News Summary: Valeant to buy Bausch + Lomb

Published



VISIONARY DEAL: Bausch + Lomb, a top maker of contact lenses, is being bought for $8.7 billion by Canadian drugmaker Valeant Pharmaceuticals to expand Valeant’s smaller ophthalmology business.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.